WILSON — Sandoz, a division of Swiss pharmaceutical manufacturer Novartis, plans to shut down a research and development operation in Wilson, putting 50 people out of work in September.
The company, which makes generic drugs, said in a filing with the N.C. Department of Commerce that it will eliminate R&D and regulatory affairs positions at the site.
The cuts will take effect around Sept. 11.
Sandoz operates a manufacturing plant in Wilson, one of three in the United States.
It's unclear whether the planned job cuts will have any effect on the factory.
Efforts to reach a Sandoz spokesman Monday were unsuccessful.